- Home>
- Specialties>
- HIV/AIDS Clinical Care>
- Initial Therapy
Search for Initial Therapy in HIV/AIDS Clinical Care
Physician-authored summaries on the latest research on initial therapy, editorials on initial therapy, and perspectives on initial therapy - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 75 results - Relevance
- Date
You searched for: initial therapy in HIV/AIDS
-
Report from the 2008 Joint ICAAC/IDSA Meeting Free
- November 10, 2008
- HIV/AIDS
The most important HIV-related findings from this year’s meeting -
Early Virologic Failure with Tenofovir/FTC + Nevirapine as Initial Therapy Free
- April 14, 2008
- Paul E. Sax, MD
- HIV/AIDS
Investigators stopped a clinical study when three of seven patients receiving tenofovir/FTC + nevirapine experienced early virologic rebound; each had evidence of multiclass viral resistance.- Reviewing:
- Lapadula G et al., Clin Infect Dis 2008 Apr 1; 46:1127.
-
Efavirenz vs. Lopinavir/Ritonavir for Initial Therapy
- February 1, 2005
- Keith Henry, MD
- HIV/AIDS
In a small nonrandomized study, open-label treatment with efavirenz and lopinavir/ritonavir resulted in similar peak CD4 counts and rates of virologic suppression; the efavirenz group had a higher CD4 count and a lower rate of AIDS at baseline.- Reviewing:
- Manfredi R et al., AIDS 2004 Nov 19; 18:2331-3.
-
Can Lopinavir/Ritonavir Be Dosed Once-Daily in Initial Therapy?
- March 1, 2004
- Bruce Soloway, MD
- HIV/AIDS
A small study suggests that once-daily and twice-daily lopinavir/ritonavir administration produce comparable clinical outcomes in treatment-naive patients, although other questions about once-daily dosing remain unanswered.- Reviewing:
- Eron JJ et al., J Infect Dis 2004 Jan 15; 189:265-72.
-
Maraviroc for Initial Treatment of HIV Infection — MERIT Reexamined Free
- March 29, 2010
- Charles B. Hicks, MD
- HIV/AIDS
Maraviroc proved noninferior to efavirenz among treatment-naive patients but is still unlikely to see much use in this population.- Reviewing:
- Cooper DA et al., J Infect Dis 2010 Mar 15; 201:803.
-
Maraviroc Now Approved for Use in Treatment-Naive HIV-Infected Patients
- December 7, 2009
- Charles B. Hicks, MD
- HIV/AIDS
The new indication maximizes the number of patients who could benefit from maraviroc, but many clinicians and patients will likely opt for agents that are simpler to use. -
Maraviroc in Treatment-Experienced and Treatment-Naive Patients Free
- September 10, 2007
- Charles B. Hicks, MD
- HIV/AIDS
Data presented at the 4th IAS Conference confirm the value of maraviroc for treatment-experienced patients, but its role in treatment-naive patients remains uncertain. -
Standard Triple-Drug Regimens Remain the Best for Initial Therapy Free
- December 29, 2006
- HIV/AIDS
Efavirenz-based regimens appear to be particularly effective. -
NNRTIs More Durable Than PIs as Initial Therapy
- December 1, 2004
- Keith Henry, MD
- HIV/AIDS
In this prospective observational study, initial NNRTI-based combination therapy led to fewer regimen changes than did initial PI-based combination therapy.- Reviewing:
- Klein MB et al. , AIDS 2004 Sep 24; 18:1895-904.
-
Abacavir as Initial Therapy and as a Once-Daily Drug
- November 1, 2003
- Paul E. Sax, MD
- HIV/AIDS
Preliminary results from two industry-sponsored studies suggested that abacavir -- currently used most commonly in treatment-experienced patients -- could be used in combination with 3TC and efavirenz as part of an initial antiretroviral regimen. -
NNRTIs Best PIs . . . Again Free
- January 8, 2007
- Paul E. Sax, MD
- HIV/AIDS
In a large randomized trial of treatment-naive patients, the most virologically active strategy was two NRTIs plus an NNRTI; a triple-class strategy yielded greater toxicity but not greater efficacy.- Reviewing:
- MacArthur RD et al., Lancet 2006 Dec 16; 368:2125-35. Abgrall S., Lancet 2006 Dec 16; 368:2107-9.
-
ACTG 384 -- Complicated, but Worth the Work
- January 1, 2004
- Paul E. Sax, MD
- HIV/AIDS
In this large, multicenter study comparing 6 different initial treatment strategies, AZT + 3TC + efavirenz emerged clearly superior to the other 5 combinations, including 4-drug triple-class regimens.- Reviewing:
- Robbins GK et al., N Engl J Med 2003 Dec 11; 349:2293-303. Shafer RW et al., N Engl J Med 2003 Dec 11; 349:2304-15. Skolnik PR et al., N Engl J Med 2003 Dec 11; 349:2351-2.
-
Is Long-Term Treatment Better with Raltegravir Than with Efavirenz? Free
- June 3, 2013
- Paul E. Sax, MD
- HIV/AIDS
Five-year follow-up of a blinded, prospective clinical trial demonstrated that raltegravir has a better side-effect profile, which ultimately leads to better outcomes.- Reviewing:
- Rockstroh JK et al., J Acquir Immune Defic Syndr 2013 May 1; 63:77.
-
Low-Level Viremia in HIV-Infected Patients: Does It Matter?
- August 20, 2012
- Rajesh T. Gandhi, MD
- HIV/AIDS
Low-level viremia predicts viral rebound, but the absolute risk is low and the next clinical step is unclear.- Reviewing:
- Maggiolo F et al., J Acquir Immune Defic Syndr 2012 Aug 15; 60:473.
-
Lopinavir/Ritonavir Superior for Young Children
- July 9, 2012
- Holly E. Rawizza, MD
- HIV/AIDS
Among young children with no prior NNRTI exposure, treatment failure was significantly less common with lopinavir/ritonavir than with nevirapine.- Reviewing:
- Violari A et al., N Engl J Med 2012 Jun 21; 366:2380.
-
Revised HIV Treatment Guidelines from the DHHS Free
- October 31, 2011
- Abigail Zuger, MD
- HIV/AIDS
This revision focuses on treatment choices for antiretroviral-naive patients.- Reviewing:
- Panel on Antiretroviral Guidelines for Adults and Adolescents., 2011 Oct 14;:
-
Etravirine and Efavirenz Show Similar Virologic Efficacy
- September 12, 2011
- Paul E. Sax, MD
- HIV/AIDS
In a randomized, double-blind trial, response rates were around 75% for both treatments.- Reviewing:
- Gazzard B et al., AIDS 2011 Aug 30;:
-
Tenofovir/FTC/Rilpivirine: A New One-Pill, Once-Daily Option for HIV Treatment
- August 15, 2011
- Paul E. Sax, MD
- HIV/AIDS
The fixed-dose combination was just approved by the FDA for use in treatment-naive HIV-infected individuals. -
HIV/AIDS Year in Review 2010
- January 3, 2011
- Paul E. Sax, MD
- HIV/AIDS
Our physician-editors offer their perspective on the year's most important stories in HIV medicine. -
HIV Drug Pipeline Promises More Fixed-Dose Combinations Free
- January 4, 2010
- Helmut Albrecht, MD
- HIV/AIDS
By 2011, providers and patients may be able to choose between several "one-pill, once-daily" options.
Sort by:
Items 1 to 20 of 75 results - Relevance
- Date
